Literature DB >> 2647860

Protective effects of murine monoclonal antibodies in experimental septicemia: E. coli antibodies protect against different serotypes of E. coli.

M F Salles1, E Mandine, R Zalisz, M Guenounou, P Smets.   

Abstract

Murine monoclonal antibodies that bind outer membrane antigens of the J5 mutant of Escherichia coli O111:B4 were derived from spleen cells of BALB/c mice immunized with killed whole cells and boosted with lipopolysaccharide (LPS) and LPS-associated proteins. Seven hybridomas were selected for their reactivity against the J5 LPS; they cross-reacted with O111, O55, O127, and O128 E. coli LPS. One (B7B3) also reacted with the Serratia marcescens LPS and Klebsiella pneumoniae lipid A. A protective effect was obtained with D6B4 antibody in a lethal endotoxemia model induced by LPS from O111, O127, and O128 E. coli serotypes in D-galactosamine-sensitized mice. D6B4 and D6B3 antibodies protected mice infected with E. coli O111:B4, when administered before infection. The D6B4 antibody was also protective when administered after infection. The antibodies D6B3 and D4B5 were protective in heterologous infection induced by E. coli O2:K1.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2647860     DOI: 10.1093/infdis/159.4.641

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Characterization of the epitope specificity of murine monoclonal antibodies directed against lipid A.

Authors:  H M Kuhn; L Brade; B J Appelmelk; S Kusumoto; E T Rietschel; H Brade
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

2.  A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate.

Authors:  Thomas A Russo; Janet M Beanan; Ruth Olson; Stacy A Genagon; Ulrike MacDonald; John J Cope; Bruce A Davidson; Brian Johnston; James R Johnson
Journal:  Vaccine       Date:  2007-02-05       Impact factor: 3.641

Review 3.  Bacteraemia in man and animals: an overview.

Authors:  J Vaid
Journal:  Vet Res Commun       Date:  1991       Impact factor: 2.459

Review 4.  Prospects for monoclonal antibodies in the diagnosis and treatment of bacterial infections.

Authors:  J Verhoef; R Torensma
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-04       Impact factor: 3.267

5.  Identification of candidates for a subunit vaccine against extraintestinal pathogenic Escherichia coli.

Authors:  Lionel Durant; Arnaud Metais; Coralie Soulama-Mouze; Jean-Marie Genevard; Xavier Nassif; Sonia Escaich
Journal:  Infect Immun       Date:  2006-12-04       Impact factor: 3.441

6.  Murine monoclonal antibodies to Klebsiella pneumoniae protect against lethal endotoxemia and experimental infection with capsulated K. pneumoniae.

Authors:  E Mandine; M F Salles; R Zalisz; M Guenounou; P Smets
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

7.  A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides.

Authors:  F E Di Padova; H Brade; G R Barclay; I R Poxton; E Liehl; E Schuetze; H P Kocher; G Ramsay; M H Schreier; D B McClelland
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

8.  Influence of some bacterial and host factors on colonization and invasiveness of Escherichia coli K1 in neonatal rats.

Authors:  M Wullenweber; L Beutin; S Zimmermann; C Jonas
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

9.  The Siderophore receptor IroN of extraintestinal pathogenic Escherichia coli is a potential vaccine candidate.

Authors:  Thomas A Russo; Catherine D McFadden; Ulrike B Carlino-MacDonald; Janet M Beanan; Ruth Olson; Gregory E Wilding
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.